drugset / Trial / NCT00492401

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00492401 ↗

Phase 2 Completed 55 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well decitabine works in treating patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Timeline

Start
2007-05
Primary completion
2010-12
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 Intravenous